Allurion Technologies Hits 52-Week Low at $1.29 Amidst Financial Struggles

Allurion Technologies, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 1.29 on November 14, 2025. This significant decline marks a staggering 94.79% drop in the company's stock price over the past year, contrasting sharply with the S&P 500's performance, which has seen a gain of 13.19% during the same period.
The company's market capitalization stands at approximately USD 17 million, reflecting its microcap status. Allurion Technologies has reported a negative book value, indicating challenges in long-term financial stability. The company's debt-to-equity ratio is -0.26, suggesting difficulties in servicing its debt obligations, with an average EBIT to interest ratio of -13.96.

Despite a reported increase in profits of 56.2%, the stock has generated a return of -85.63% over the past year, highlighting a consistent underperformance against the S&P 500. The latest financial results indicate a concerning trend, with net sales recorded at their lowest at USD 3.38 million, alongside an 11.18% year-over-year increase in raw material costs.